Neuro-Oncology Reviews
Volume
28 Number 14
20 May 2026
Home > Publications > Neuro-Oncology Reviews > Volume 28, Year 2026 > Number 14, 20 May
Gao R, Gong Z, He Y, Jiang Y,
Duan H, Wang H.
Emerging
frontiers in glioma therapy: the evolving role of glioma vaccines.
Front
Immunol. 2026
May 11;17:1781820. doi:
10.3389/fimmu.2026.1781820. PMID:
42199419. ˍ
Steuart
SJ, Grewal EP, Sun J, Richardson LGK, Bulow US, Garcia-Beltran WF,
Curry WT Jr, Choi BD.
Next-generation
CAR-NK cell therapy for glioblastoma: strategies to overcome
antigen escape and the immunosuppressive tumor microenvironment.
Expert
Opin Biol Ther.
2026 May 11;26(5):437-440. doi:
10.1080/14712598.2026.2672421. PMID:
42113024. ˍ
Vargas LO, Latzman S, Tickoo L, Abikenari M, Syed SA, Mittelman L,
Cassimatis N, Teng CL, Sistiaga IL, D'Amico RS.
Gliomas
as network diseases: Neuron-tumor interactions, connectome
disruption, and clinical implications.
Clin
Neurol Neurosurg. 2026 May 11;267:109475. doi:
10.1016/j.clineuro.2026.109475. PMID:
42119240˰ ˍ
Blum CB, McMenamin M, Khoo T,
Edwin JM, Jose P, O'Callaghan LA.
From
anthelmintic to neuro-oncology: A systematic review of mebendazole
repurposing for brain tumour therapy.
Br
J Clin Pharmacol.
2026 May 12. doi:
10.1002/bcp.70565. PMID:
42120351. ˍ
van den Bent MJ.
Gods
do play dice: The activity of regorafenib in glioblastoma not
confirmed.
Neuro
Oncol. 2026
May 12:noag109. doi:
10.1093/neuonc/noag109. PMID:
42124532˰
ˍ
Liu D, Liu Y, Ci Y, Wang C, Ma
W.
Efficacy
and safety of targeted therapies for glioblastoma: a systematic
review and network meta-analysis.
BMC
Cancer. 2026
May 18. doi:
10.1186/s12885-026-16190-0. PMID:
42151869. ˍ
Kotch C, Perreault S, Power P,
Adams DJ, Aldape K, Avery RA, Bandopadhayay P, Capper D, de Blank
P, Entz-Werle N, Fangusaro J, Hansford JR, Hawkins C, Jacques TS,
Jones DT, Kann BH, Kranendonk ME, Levine A, Ligon KL,
Martinez-Barbera JP, Meijer L, Milde T, Mueller S, Mulcahy Levy
JM, Nakano Y, Packer RJ, Pfister S, Raabe E, Robison NJ, Tabori U,
Yeo KK, Vinitsky A, Zhu Y, Fisher MJ, Hargrave D, Kilburn LB.
Tempered
Optimism: Advances in the Precision Medicine Era for Pediatric
Low-Grade Glioma.
Neuro
Oncol. 2026
May 19:noag111. doi:
10.1093/neuonc/noag111. PMID:
42155029. ˍ
Abuliezi N, Sun Y, Zhao J, Qu X,
Wu Y, Liao T, Kuerban G, Dun X, Wu Q.
Efficacy
and safety of tumor treating fields (TTF) combined with
chemotherapy versus chemotherapy only in the treatment of
glioblastoma: a systematic review and meta-analysis.
Front
Med (Lausanne).
2026 May 8;13:1812119. doi:
10.3389/fmed.2026.1812119. PMID:
42180742. ˍ
Dvir
R, Elhasid R, Roth J, Constantini S, Peled Y, Ospovat I, Shiran
SI.
Pediatric
metastatic medulloblastoma: upfront biopsy followed by oncological
treatment without excision of the primary tumor.
J
Neurosurg Pediatr.
2026 May 8:1-8. doi: 10.3171/2025.12.PEDS25467. PMID: 42102399. ˍ
Sung
JY, Hwang K.
Glioblastoma:
epidemiology, molecular pathogenesis, diagnosis, management, and
therapeutic resistance.
Mol
Biomed.
2026 May 8;7(1):63. doi:
10.1186/s43556-026-00467-8. PMID:
42101535. ˍ
Welch RL, Moziak K, Zang X,
Martin AM.
Immune
checkpoint inhibitors in medulloblastoma: current updates in
preclinical and clinical developments.
Front
Oncol. 2026
May 8;16:1725230. doi:
10.3389/fonc.2026.1725230. PMID:
42180054. ˍ